問卷

TPIDB > Search Result

Search Result

篩選

List

766Cases

2019-01-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2012-05-01 - 2018-12-03

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2021-11-01 - 2025-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2016-11-01 - 2024-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-11-01 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2024-01-12 - 2026-09-11

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  • Test Drug

    Efruxifermin

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Study ended1Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2013-06-01 - 2015-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites